Tag: biosimilar

Anti-tumor necrosis factor (TNF) therapies are commonly used in the treatment of patients with moderate to severe Crohn’s disease. However, due to the high costs of anti-TNF medications, biosimilar medications are being developed. These drugs have high likeness to already licensed biological therapies and are subject to strict approval...
1. The biosimilar to infliximab, CT-P13 was shown in this study to have equivalent efficacy to the anti tumor-necrosis factor (TNF) monoclonal antibody for Crohn’s treatment. 2. There was no significant safety differences observed in this study between the two treatments for Crohn’s disease. Evidence Rating Level: 2 (Good) Study Rundown: Crohn’s...